Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vibativ
Synonyms :
Telavancin
Class :
Glycopeptide antibiotics
Brand Name :
Vibativ
Synonyms :
Telavancin
Class :
Glycopeptide antibiotics
Dosage forms and strengthsÂ
injection, lyophilized powderÂ
(750mg/vial)Â
Safety and efficacy are not established.Â
Refer adult DosingÂ
may decrease the therapeutic effect when combined with heparin
QTc interval is increased both by lenvatinib and telavancin
when used together, entrectinib and midostaurin both increase the QTc interval
when used together, encorafenib and midostaurin both increase the QTc interval
It may enhance QTc interval when combined with lithium
It may enhance the risk of adverse effects when combined with Glycopeptides
It may enhance the risk of adverse effects when combined with Glycopeptides
abacavir might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
aceclofenac might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
acemetacin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
acetaminophen might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
acyclovir might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
adefovir dipivoxil might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
alclofenac might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
aldesleukin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
allopurinol might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
almotriptan might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
alogliptin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
alprazolam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
aminophenazone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
amoxicillin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
amphetamine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
amphotericin b might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ampicillin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
amrinone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
antipyrine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
antrafenine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
apremilast might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
auranofin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
azacitidine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
azathioprine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
azelaic acid might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
aztreonam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bacitracin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
baclofen might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
balsalazide might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
benorilate might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
benoxaprofen might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
benzydamine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bepotastine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bisoprolol might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bleomycin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
brivaracetam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bromazepam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
budesonide might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bumadizone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
bupropion might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
buspirone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
butabarbital might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
capecitabine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
carbidopa might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
carboplatin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
carmustine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
carprofen might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefaclor might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefadroxil might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefalotin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefamandole might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefapirin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefazolin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefdinir might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefditoren might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefepime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefmenoxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefmetazole might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefonicid might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefoperazone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ceforanide might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefotaxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefotetan might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefotiam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefoxitin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefpiramide might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefpodoxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefprozil might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefradine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ceftazidime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ceftibuten might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ceftizoxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ceftobiprole might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
ceftriaxone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cefuroxime might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
celecoxib might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cephalexin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cephaloglycin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cevimeline might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
chloral hydrate might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
chlorpropamide might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
chlorzoxazone might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
choline magnesium trisalicylateÂ
choline magnesium trisalicylate might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cidofovir might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cimetidine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
clevidipine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
clobazam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
clofarabine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
clonazepam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
clorazepic acid might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
colchicine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cyanocobalamin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
cyclosporine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
dacarbazine might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
daptomycin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
desmopressin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
dexibuprofen might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
dexketoprofen might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
dexrazoxane might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
diatrizoate might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
diazepam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
diclofenac might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
acetaminophen/dextromethorphan/pseudoephedrine/guaifenesin
It may enhance the risk of adverse effects when combined with Decongestant
brompheniramine, dextromethorphan and phenylephrine
It may enhance the risk of adverse effects when combined with Decongestant
It may enhance the risk of adverse effects when combined with Decongestant
It may enhance the risk of adverse effects when combined with Glycopeptides
acetaminophen IV/ibuprofen IV (Pending FDA Approval)
It may enhance the risk of adverse effects when combined with Glycopeptides
It may enhance the risk of adverse effects when combined with Glycopeptides
It may enhance the risk of adverse effects when combined with Glycopeptides
It may enhance the risk of adverse effects when combined with Glycopeptides
cefpirome might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
when used in combination, pazopanib and telavancin both increase the QTc interval
Actions and Spectrum:Â Â
telavancin is a semisynthetic lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the terminal D-alanyl-D-alanine residues of the peptidoglycan precursor, thus inhibiting transglycosylation and transpeptidation. This leads to bacterial cell death and the effective treatment of infections.Â
telavancin demonstrates a broad spectrum of activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and Streptococcus pneumoniae, among others. It also exhibits some activity against gram-negative bacteria, although to a lesser extent.Â
Frequency definedÂ
>10%Â
AdultsÂ
VomitingÂ
Foamy urineÂ
Taste disturbanceÂ
NauseaÂ
 AdultsÂ
1-10%Â
RigorsÂ
PruritusÂ
RashÂ
DiarrhoeaÂ
dizzinessÂ
Black Box Warning:
telavancin has a black box warning regarding the risk of foetal harm, including a potential risk of foetal death. telavancin is classified as a Pregnancy Category C medication, meaning that it has been shown to have adverse effects on animal foetuses in studies, but there are no adequate and well-controlled studies in pregnant women.Â
Therefore, telavancin should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus. Women of childbearing age should undergo pregnancy testing prior to starting telavancin therapy and use effective contraception during treatment.Â
Â
Contraindication/Caution:Â Â
Anaphylaxis and severe hypersensitivity reactions, including angioedema and severe skin reactions, have been reported in patients receiving telavancin.Â
Additionally, telavancin should not be used in patients with a history of vancomycin-associated allergic reactions or nephrotoxicity, as Telavancin may cause similar adverse reactions.Â
telavancin is also contraindicated in patients with a creatinine clearance (CrCl) of less than 30 mL/min, as it is primarily eliminated through renal excretion. In patients with severe renal impairment, the risk of nephrotoxicity may be increased, and alternative treatment options should be considered.Â
Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:
telavancin is a semi-synthetic lipoglycopeptide antibiotic that exerts its antibacterial effects by inhibiting cell wall synthesis. Telavancin binds to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the growing peptidoglycan chain, thereby preventing its incorporation into the bacterial cell wall. This results in inhibition of bacterial cell wall synthesis, leading to cell death.Â
Pharmacodynamics:Â
Its pharmacodynamic mechanism involves the inhibition of bacterial cell wall synthesis by targeting the cell membrane and disrupting its integrity.Â
The primary target of telavancin is the terminal D-alanyl-D-alanine residues of the nascent peptidoglycan chains that make up the bacterial cell wall. Telavancin binds to these residues with high affinity, which leads to the inhibition of the transglycosylation and transpeptidation steps in cell wall synthesis. Â
MOA:Â Â
telavancin binds to the terminal D-alanyl-D-alanine residues of the nascent peptidoglycan chains that make up the bacterial cell wall. This binding leads to the inhibition of transglycosylation and transpeptidation, which are essential steps in the formation of the bacterial cell wall.Â
Pharmacokinetics:Â
AbsorptionÂ
telavancin is administered intravenously (IV), so it bypasses the absorption phase. The bioavailability of Telavancin is 100%.Â
DistributionÂ
telavancin has a volume of distribution (Vd) of approximately 0.18 L/kg. It is highly protein-bound (more than 90%) to serum albumin.Â
MetabolismÂ
telavancin is not extensively metabolized, and it does not undergo significant hepatic metabolism. It is primarily eliminated unchanged by the kidneys.Â
Elimination and ExcretionÂ
The elimination half-life of telavancin is approximately 7.5 hours. It is eliminated primarily through the kidneys, with approximately 80% of the drug excreted unchanged in the urine.Â
Administration: Â
telavancin is administered through a vein in the arm or hand using a sterile IV catheter. The healthcare professional will monitor the patient’s response to the medication and adjust the dosage if necessary.Â
Patient information leafletÂ
Generic Name: telavancinÂ
Why do we use telavancin? Â
It is a type of antibiotic medication that belongs to the class of drugs called lipoglycopeptides. telavancin works by inhibiting the synthesis of bacterial cell walls, which leads to the death of the bacteria.Â
Some of the infections that telavancin can be used to treat include:Â
Skin and skin structure infections: These are infections that affect the skin, subcutaneous tissue, and underlying structures such as muscles and bones. Examples include cellulitis, abscesses, and infected wounds. Â
Hospital-acquired pneumonia: This is a type of pneumonia that occurs in patients who are hospitalized for another illness. It is caused by bacteria that are often resistant to other antibiotics.Â
Bacteremia: This is a bacterial infection of the bloodstream. It can be caused by a variety of bacteria, including Staphylococcus aureus and Enterococcus faecalis.Â
Â
Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
